1. Home
  2. UA vs CELC Comparison

UA vs CELC Comparison

Compare UA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Under Armour Inc. Class C

UA

Under Armour Inc. Class C

HOLD

Current Price

$6.30

Market Cap

3.4B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$122.68

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UA
CELC
Founded
1996
2011
Country
United States
United States
Employees
14400
N/A
Industry
Apparel
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
UA
CELC
Price
$6.30
$122.68
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$107.88
AVG Volume (30 Days)
2.3M
661.2K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.57
$720.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.95
$9.64
52 Week High
$7.91
$127.34

Technical Indicators

Market Signals
Indicator
UA
CELC
Relative Strength Index (RSI) 56.80 57.50
Support Level $6.24 $99.38
Resistance Level $6.44 N/A
Average True Range (ATR) 0.26 5.29
MACD 0.08 0.90
Stochastic Oscillator 82.79 75.39

Price Performance

Historical Comparison
UA
CELC

About UA Under Armour Inc. Class C

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: